How Lilly Aims To Make Sure Good Drugs Don't Get Lost In Translation
SVP/CSO Daniel Skovronsky says the company has invested in technology and biotech-like teams to speed up the process of translating targets identified in house into human data for novel drugs.
You may also be interested in...
The company will focus on core therapeutics areas like oncology and cardiovascular disease, but left open the possibility of future work in neuroscience with a genetic basis for drug development.
The New Year is just a week old but the biopharma merger and acquisitions merry-go-round is already spinning furiously as Lilly now steps in with a proposal to buy Loxo.
Chief Scientific Officer Dan Skovronsky has remit over business development at Eli Lilly, and he said the company is looking to do more deals, including higher-risk early stage molecules and new modalities, during an investor briefing in New York Dec. 19. The company also provided 2019 financial forecasts.